EE9700328A - Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine - Google Patents

Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine

Info

Publication number
EE9700328A
EE9700328A EE9700328A EE9700328A EE9700328A EE 9700328 A EE9700328 A EE 9700328A EE 9700328 A EE9700328 A EE 9700328A EE 9700328 A EE9700328 A EE 9700328A EE 9700328 A EE9700328 A EE 9700328A
Authority
EE
Estonia
Prior art keywords
preparation
active ingredient
solid oral
containing olanzapine
preparation containing
Prior art date
Application number
EE9700328A
Other languages
English (en)
Other versions
EE03551B1 (et
Inventor
Randall Cochran George
Clifford Morris Tommy
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9700328(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of EE9700328A publication Critical patent/EE9700328A/et
Publication of EE03551B1 publication Critical patent/EE03551B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EE9700328A 1995-03-24 1996-03-22 Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine EE03551B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24
PCT/US1996/003918 WO1996029995A1 (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation

Publications (2)

Publication Number Publication Date
EE9700328A true EE9700328A (et) 1998-06-15
EE03551B1 EE03551B1 (et) 2001-12-17

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700328A EE03551B1 (et) 1995-03-24 1996-03-22 Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine

Country Status (46)

Country Link
US (4) US5919485A (et)
EP (2) EP0733367B1 (et)
JP (1) JPH11502848A (et)
KR (1) KR100408172B1 (et)
CN (1) CN1178662C (et)
AP (1) AP679A (et)
AR (2) AR001405A1 (et)
AT (3) AT405606B (et)
AU (1) AU696601B2 (et)
BG (1) BG62594B1 (et)
BR (1) BR9607791A (et)
CA (1) CA2216372C (et)
CH (1) CH691217A5 (et)
CO (1) CO4700474A1 (et)
CR (1) CR5278A (et)
CZ (1) CZ296007B6 (et)
DE (3) DE19681287T1 (et)
DK (3) DK0733367T3 (et)
EA (1) EA000938B1 (et)
EE (1) EE03551B1 (et)
EG (1) EG24077A (et)
ES (2) ES2164837T3 (et)
FI (1) FI973749A (et)
GB (1) GB2313783B (et)
HU (1) HU225269B1 (et)
IL (1) IL117611A (et)
IS (1) IS1903B (et)
LT (1) LT4350B (et)
LU (1) LU90115B1 (et)
LV (1) LV11983B (et)
MY (1) MY113440A (et)
NO (1) NO320388B1 (et)
NZ (1) NZ306111A (et)
OA (1) OA10511A (et)
PE (1) PE44997A1 (et)
PL (1) PL188316B1 (et)
PT (2) PT733367E (et)
RO (1) RO118370B1 (et)
SE (1) SE9703206D0 (et)
SI (3) SI9620041A (et)
SK (1) SK283745B6 (et)
TR (1) TR199701018T1 (et)
TW (1) TW426526B (et)
UA (1) UA44766C2 (et)
WO (1) WO1996029995A1 (et)
ZA (1) ZA962338B (et)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
PT1246827E (pt) * 1999-12-28 2005-08-31 Cipla Ltd Novas formas polimerficas da olanzapina
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7029112B2 (en) * 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
EP1670441A4 (en) * 2003-10-07 2012-05-02 Andrx Pharmaceuticals Llc FAST RESOLUTION FORMULATION
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20060240101A1 (en) * 2005-04-22 2006-10-26 Shubha Chungi Orally disintegrating pharmaceutical tablet formulations of olanzapine
AU2006253007B2 (en) * 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
AU2006253006B8 (en) * 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
ATE465720T1 (de) * 2006-07-05 2010-05-15 Bilim Ilac Sanayii Ve Ticaret Stabile olanzapin-formulierung mit antioxidantien
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
KR101528953B1 (ko) * 2008-01-31 2015-06-15 교린 세이야꾸 가부시키 가이샤 이미다페나신을 유효 성분으로 하는 구강 내 속붕정의 제조 방법
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
JP2012522204A (ja) * 2009-03-25 2012-09-20 カイティン、インコーポレーテッド 超音速冷却システム
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
EP4378463A2 (en) * 2017-06-02 2024-06-05 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
DE69329887T2 (de) * 1992-05-29 2001-05-23 Lilly Co Eli Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
US7229643B2 (en) 2007-06-12
IS1903B (is) 2003-11-20
ES2164837T3 (es) 2002-03-01
NO320388B1 (no) 2005-11-28
SE9703206L (sv) 1997-09-05
EP0733367B1 (en) 2001-10-17
HUP9800410A3 (en) 2000-01-28
ZA962338B (en) 1997-09-22
TR199701018T1 (xx) 1998-01-21
US5919485A (en) 1999-07-06
KR19980703189A (ko) 1998-10-15
GB9719817D0 (en) 1997-11-19
DE69615887T2 (de) 2002-04-11
LT97149A (en) 1998-01-26
FI973749A0 (fi) 1997-09-22
DK173323B1 (da) 2000-07-24
TW426526B (en) 2001-03-21
HU225269B1 (en) 2006-08-28
US6780433B2 (en) 2004-08-24
ATE284695T1 (de) 2005-01-15
AU696601B2 (en) 1998-09-17
IS4565A (is) 1997-09-22
DE19681287T1 (de) 1998-03-19
CA2216372C (en) 2007-11-20
CA2216372A1 (en) 1996-10-03
AP9701064A0 (en) 1997-10-31
EP1093815B1 (en) 2004-12-15
PT733367E (pt) 2002-03-28
EE03551B1 (et) 2001-12-17
NO974363L (no) 1997-11-17
NZ306111A (en) 1999-02-25
ATE206924T1 (de) 2001-11-15
AR002720A1 (es) 1998-04-29
MX9707186A (es) 1997-11-29
EP0733367A1 (en) 1996-09-25
AT405606B (de) 1999-10-25
SI0733367T1 (en) 2002-06-30
MY113440A (en) 2002-02-28
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
WO1996029995A1 (en) 1996-10-03
CO4700474A1 (es) 1998-12-29
NO974363D0 (no) 1997-09-22
CZ300197A3 (en) 1997-12-17
US20050085462A1 (en) 2005-04-21
CR5278A (es) 1996-07-04
KR100408172B1 (ko) 2004-02-18
SK283745B6 (sk) 2003-12-02
UA44766C2 (uk) 2002-03-15
JPH11502848A (ja) 1999-03-09
HUP9800410A2 (hu) 1998-07-28
AU5428096A (en) 1996-10-16
EP1093815A1 (en) 2001-04-25
GB2313783B (en) 1998-11-18
DK1093815T3 (da) 2005-04-25
LU90115B1 (fr) 1997-09-10
SE9703206D0 (sv) 1997-09-05
BG62594B1 (bg) 2000-03-31
SI1093815T1 (en) 2005-06-30
FI973749A (fi) 1997-09-22
EA000938B1 (ru) 2000-06-26
DE69634053T2 (de) 2005-12-22
IL117611A0 (en) 1996-07-23
DK0733367T3 (da) 2001-11-26
DE69634053D1 (de) 2005-01-20
AP679A (en) 1998-09-28
DK109097A (da) 1997-11-12
CZ296007B6 (cs) 2005-12-14
PE44997A1 (es) 1997-10-23
EA199700260A1 (ru) 1998-02-26
GB2313783A (en) 1997-12-10
ATA902296A (de) 1999-02-15
LV11983B (en) 1998-07-20
PT1093815E (pt) 2005-03-31
OA10511A (en) 2002-04-24
US20010018071A1 (en) 2001-08-30
BG101901A (en) 1998-10-30
ES2232379T3 (es) 2005-06-01
CN1178662C (zh) 2004-12-08
US6190698B1 (en) 2001-02-20
AR001405A1 (es) 1997-10-22
IL117611A (en) 2002-05-23
CN1179102A (zh) 1998-04-15
DE69615887D1 (de) 2001-11-22
LT4350B (lt) 1998-05-25
CH691217A5 (de) 2001-05-31
RO118370B1 (ro) 2003-05-30
BR9607791A (pt) 1998-07-07
PL188316B1 (pl) 2005-01-31
SI9620041A (sl) 1998-06-30
EG24077A (en) 2008-05-11
LV11983A (lv) 1998-03-20

Similar Documents

Publication Publication Date Title
EE9700328A (et) Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine
EE9800180A (et) Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE9800181A (et) Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE04417B1 (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
PL304060A1 (en) Solid dosed form of prolonged release for oral administration and method of obtaining same,
EE9700061A (et) Farmatseutiline aerosoolpreparaat ja selle valmistamismeetod
EE9800304A (et) Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
HK1015269A1 (en) Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
EE03676B1 (et) Mullpakend, selle valmistamise meetod ja mullpakendi kasutamine
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
FI962908A (fi) Mikrobinvastainen koostumus, sen valmistusmenetelmä ja sen käyttö
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
ATE220547T1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE200000099A (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
NO975567D0 (no) Preparat med kontrollert frigivelse av aktiv substans
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE9800075A (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
HUP0001773A3 (en) Substituted tetrahydropyridin derivatives, method of preparation and pharmaceutical compositions containing them
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
NO975680D0 (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231